i3 Health Podcast: Recent Episodes
i3 Health
i3 Health's mission is to enhance the proficiency of the multidisciplinary health care team by providing evidence-based, fair-balanced CME/NCPD/CPE activities that address identified professional practice gaps and unmet educational needs.
Are you treating extrapulmonary neuroendocrine carcinomas based on where they start—or what they actually are?In this faculty follow-up to their i3 Health activity (Clinical Challenges in Extrapulmonary NEC: Expert Insights on Diagnosis, Treatment, and Emerging Targets), Andrew Hendifar, MD, and Danielle Hutchings, MD (Cedars-Sinai Medical Center), unpack why treating these rare, aggressive tumors according to site of origin rather than tumor lineage can compromise outcomes. They clarify crucial pathologic distinctions between well-differentiated neuroendocrine tumors (NETs) and poorly differentiated neuroendocrine carcinomas (NECs) while emphasizing the essential role of multidisciplinary collaboration in precision care.The experts also explore the novel therapeutic landscape of delta-like ligand 3 (DLL3)–targeted therapies, highlighting the promise of DLL3 T-cell engagers in extrapulmonary disease. They address ongoing diagnostic hurdles—such as standardized immunohistochemistry (IHC) expression thresholds and expanding send-out testing access—while sharing key insights on emerging clinical trials evaluating T-cell engager monotherapies and chemo-immunotherapy combinations.Claim your CME credit: https://bit.ly/488fPhKDownload and review the companion Clinical Challenges in Extrapulmonary NEC Slide Deck: https://bit.ly/4w2Pni3
What if hitting prostate cancer earlier and harder is the key to delaying disease progression and sparing patients from invasive salvage therapies?In this follow-up to his i3 Health Virtual Tumor Board, Stephen Freedland, MD, Cedars-Sinai Medical Center, unpacks practice-changing data from ASCO that is actively reshaping care algorithms across the prostate cancer continuum. Dr. Freedland dives into the breakthrough TALAPRO-3 trial—exploring why talazoparib plus enzalutamide is making waves across diverse HRR alterations (including BRCA and ATM)—and analyzes how the PROTEUS trial’s 35% reduction in subsequent salvage therapies could redefine surgical planning for high-risk localized disease. Plus, get an insider's look at what’s on the horizon with PSMA PET imaging, T-cell engagers, and AR degraders.🎓Complete the Educational Activity: bit.ly/4x2BnWf
Chronic inflammatory demyelinating polyneuropathy (CIDP) presents significant challenges in both diagnosis and long-term disease management. As consensus definitions, emerging targeted therapies, and research into serologic biomarkers evolve, how can clinicians optimize individual care algorithms?In this follow-up discussion, Karissa Gable, MD, Duke University Medical Center, breaks down recent breakthroughs in CIDP care and trial design:- Standardizing CIDP Terminology: Key updates from the new international consensus definitions paper establishing unified criteria for disease remission, stability, treatment response, and refractory disease.- The Emerging Pipeline: What’s next in therapeutic development, including FcRn antagonists (nipocalimab and batoclimab) and complement inhibitors.- Shared Decision-Making: Practical strategies for tailoring therapy selection based on patient preferences, lifestyle, comorbidities, and administration routes.- Building Confidence in CIDP Care: Applying 2021 EAN/PNS guidelines to navigate diagnosis and ongoing treatment adjustments when first-line options fall short.💡 Complete the Educational Activity: bit.ly/4pPcVWe👉 Access the accompanying slide deck for comprehensive guidance on CIDP detection and management: bit.ly/4pPcVWe
Frontline treatment selection for newly diagnosed multiple myeloma (NDMM) is more complex than ever. With quadruplet regimens and anti-CD38 antibodies redefining the landscape, how do you choose the right therapy for each unique patient?In this exclusive preview, Ashley Chen, PharmD, BCOP (Fred Hutchinson Cancer Center), shares actionable insights on:🔹The Nuances of Modern Selection: Balancing comorbidities and logistical hurdles.🔹Managing Induction Burden: Proactive strategies for steroid side effects and neuropathy.🔹Pragmatic Dosing: Finding the most sustainable, real-world dose for frail or older patients.📅 Save Your Spot for the Live Event!Get case-based guidance from Dr. Rahul Banerjee, Dr. Ashley Chen, and Dr. Beth Faiman.Session 1: July 8 at 6:00 pm ET: https://bit.ly/3SitVaCSession 2: July 28 at 7:00 pm ET: https://bit.ly/4oIAcZo
or mild compared to the severe jaundice seen in infants.Diagnostic Red Flags: When to move beyond standard autoimmune panels and look for genetic markers.Genetic Testing 101: A comparison of targeted gene panels vs. whole exome sequencing for the most efficient diagnosis.The Power of a Name: How a specific PFIC diagnosis changes everything—from family counseling to starting life-altering IBAT inhibitors.💡 Earn 1.5 Free CME/AAPA Credits👉 Join the Escape Room: i3health.com/pfic
is the new benchmark in localized disease and how to integrate these advances into your clinical practice today.Interested in the complete CE activity?Complete Module 1: https://bit.ly/45u106oComplete Module 2: https://bit.ly/3HtOziO
Click here to view the full CME/NCPD/CPE/AAPA activity and hear additional insights on the HER2-mutant NSCLC treatment landscape! https://i3health.com/course-information/nsclc-advances The FDA’s recent expanded approval of zongertinib marks a significant milestone in the treatment of non-small cell lung cancer (NSCLC). As the first oral human epidermal growth factor receptor 2 (HER2) inhibitor to move into the frontline setting, this therapy offers a new standard of care for patients with metastatic or unresectable non-squamous NSCLC harboring HER2 mutations. Following the approval, Beth Sandy, Thoracic Oncology Nurse Practitioner at the University of Pennsylvania, sat down to explore its clinical implications, including efficacy data, side effect management, and the potential of having a once-daily oral pill for improving patient experiences.
perspective clinicians need to stay ahead. Listen now to discover what the future holds for hemophilia management! Click here to complete the activity, Raising the Bar for Hemophilia Management, and claim your CME credit: https://bit.ly/3Ini6vj
Schizophrenia is far more than hallucinations and delusions. In this Faculty Follow-Up, Christoph U. Correll, MD—Professor of Psychiatry and Molecular Medicine at the Zucker School of Medicine at Hofstra/Northwell and Chair of Child and Adolescent Psychiatry at Charité University in Berlin—joins us to unpack the full multidimensional nature of schizophrenia.Dr. Correll explores how our understanding of positive, negative, and cognitive symptoms continues to evolve, why these domains matter for real-world functioning, and how to better identify and treat often-overlooked symptom clusters. He also highlights practical strategies for multidisciplinary collaboration, engaging patients and families in shared decision making, and integrating emerging evidence into everyday practice to optimize outcomes.To dive deeper into this topic and earn CME/NCPD/AAPA/CPE credit, view Dr. Correll’s full activity and here: https://bit.ly/3KSTtHK
Neuroendocrine tumor (NET) care is changing fast—and the pace of innovation is only accelerating. In this episode, Aman Chauhan, MD, Associate Professor of Clinical Medicine at the University of California, San Francisco (UCSF), breaks down the latest advances that are reshaping how clinicians diagnose and treat NETs.Dr. Chauhan, who recently chaired i3 Health’s CME activity Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, returns to highlight what’s new and what matters most for practice. From evolving epidemiologic insights to emerging targeted therapies and next‑generation immunotherapies, he explains how these developments are expanding options for patients and refining real‑world decision making.Whether you’re a clinician treating NETs, a trainee looking to stay current, or a listener interested in where cancer care is headed next, this conversation offers a concise, high‑yield tour of the NET landscape—and where it’s going next.Click the link to view the full activity and claim your free CME credit: bit.ly/41Qo65YClick here to download/view the infographic: bit.ly/4bbSUmL
Biliary tract cancers, including cholangiocarcinoma, are among the most complex and aggressive malignancies in oncology. In this episode, we are joined by Melinda Bachini, Chief Patient Officer at the Cholangiocarcinoma Foundation and a remarkable 16-year survivor of stage IV intrahepatic cholangiocarcinoma. Following her participation in i3 Health’s Multidisciplinary Task Force, Melinda shares her unique perspective on the challenges of diagnosis, the critical role of clinical trials, and how the advocacy community is driving innovation forward.Whether you are a clinician looking for multidisciplinary insights or a patient seeking hope and resources, this conversation highlights the vital intersection of medical advancement and the patient voice.Explore more from the Task Force:Earn Credit: Listen to the CME/NCPD/AAPA-accredited podcast here: https://bit.ly/40unnqtWatch the Discussion: View the full Task Force recording on YouTube: https://www.youtube.com/live/ZuJpHcqi7dYRead the Research: Access the official Position Statement in Hepatology Communications: https://bit.ly/4b3JpFb
The management of ulcerative colitis (UC) has moved far beyond simple symptom control, evolving into a sophisticated era of precision medicine fueled by an ever-expanding therapeutic armamentarium. Following his popular CME/AAPA-accredited Virtual UC Escape Room, Benjamin Cohen, MD—Co-Section Head and Clinical Director of IBD at the Cleveland Clinic—dives back into the shifting paradigms of modern care. Dr. Cohen breaks down the latest updates in disease management and identifies the critical priorities clinicians must master to optimize outcomes in today’s fast-paced practice environment.Ready to test your clinical skills? Visit i3health.com/uc-escape to challenge yourself in the Virtual Escape Room!
This Multidisciplinary Task Force explores strategies for increasing early intervention and optimizing management of psoriatic arthritis. It features perspectives from a panel of experts discussing therapies for treatments, early diagnosis and and screenings. For more information please visit: https://bit.ly/3RhdDuH
Slowing Disease Progression and Optimizing Quality of Life for Patients with ALS, returns to highlight the latest developments that are already informing clinical practice—and bringing renewed optimism to both clinicians and the patients they serve.Click here to view the full activity and claim your free credit: https://bit.ly/4qbRoXh
With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 2 of the full podcast activity. Click the link to complete module 2 and claim your free credit: https://bit.ly/44yO9RB
With numerous new developments in melanoma treatment over recent months, Dr. Davies sat down again to share these critical updates that are impacting practice. After the interview, stay tuned to hear module 1 of the full podcast activity. Click the link to complete module 1 and claim your free credit: https://bit.ly/4iYmYD2
Ready to close the gap in HER2-mutant NSCLC care? Join Memorial Sloan Kettering experts Helena A. Yu, MD, and Maria Arcila, MD, for a live webinar on optimizing HER2 testing and integrating the latest targeted therapies into your practice. They’ll walk through how to improve detection and ensure your patients are getting the most effective, up-to-date treatments available.You can catch the live session on either of these dates:Wednesday, January 8 at 5:00 pm ET: bit.ly/4iZxnA0Monday, January 26 at 5:00 pm ET: bit.ly/4qALw9J
Join Lauren M. Madigan, MD, Associate Professor of Dermatology at the University of Utah, for a sneak peek at our upcoming live webinar, Beyond the Skin: Uncovering Systemic Mastocytosis (SM) in Dermatology Practice. In this short interview, Dr. Madigan shares practical insights on why SM is so often diagnosed late, how skin findings can be a key clue to recognition, and what’s new in the rapidly evolving world of targeted therapies.The webinar will be offered on two dates. Click the links to register for the date that fits your schedule best!Tuesday, January 13 at 5:00 pm ET - https://bit.ly/4p7HRilMonday, February 2 at 7:00 pm ET - https://bit.ly/495gnEd
Christoph U. Correll, MD, Professor of Psychiatry and Molecular Medicine at the Zucker School of Medicine at Hofstra/Northwell and Chair of Child and Adolescent Psychiatry at Charité University in Berlin, is currently chairing i3 Health’s four-part educational activity, Schizophrenia Update: Navigating the Latest in Research and Treatment. In this interview, he shares recent updates in schizophrenia research and explains why education is so critical for clinicians to optimize their patients’ outcomes.Click here to listen to the full activity podcasts! Module 1: https://bit.ly/3JsEYKfModule 2: https://bit.ly/436dYa5Module 3: https://bit.ly/47fkz4pModule 4: https://bit.ly/4oflWWZ
Don't forget to claim your credit after the episode!Click on the link to claim your credit for module 2: bit.ly/43VoFNP
Don't forget to claim your credit after the episode!Click on the link to claim your credit for module 1: bit.ly/3Y3ivHMClick here to continue listening to Module 2 of this podcast series: bit.ly/43VoFNP
Psoriatic arthritis care is rapidly evolving, demanding multidisciplinary collaboration and timely access to evidence-based therapies for optimal patient outcomes. i3 Health's Multidisciplinary Task Force—Increasing Early Intervention and Optimizing Management in Psoriatic Arthritis—convened expert clinicians and a patient moderator to address real-world challenges in screening, diagnosis, comorbidity management, and therapeutic optimization.In this follow-up interview, Archie Franklin, MBA, a psoriatic arthritis patient and Task Force moderator, shares insights on the discussion, the changing treatment landscape, and practical guidance for elevating standards of care.Click here to view the Task Force and claim your CE credit: https://bit.ly/4h5NSKb
Transform your approach to CLL care with insights from clinical pharmacy expert, "Kelsey Marciano, PharmD, BCOP,UCHealth. This podcast unpacks the latest strategies for treatment selection and toxicity management—empowering oncology pharmacists to lead confidently, maximize patient outcomes, and deliver next-level care in the evolving era of oral targeted therapies.🎧 Listen now and click the link to claim your CE credit!Claim your credit here: https://bit.ly/4pGrLO5🔗 Learn more and access continuing education activities: https://i3health.com📲 Stay connected with i3 Health:Twitter/X: https://bit.ly/42VAYs1LinkedIn: https://bit.ly/3IMiCmvFacebook: https://bit.ly/46JrQI2YouTube: https://bit.ly/4pNhWxRInstagram: https://bit.ly/4nUSNzEThreads: https://bit.ly/3Wd6oq9🎧 Subscribe to the i3 Health Podcast on your favorite streaming platform so you never miss the latest expert discussions!
Extrapulmonary neuroendocrine carcinomas (EP-NECs) are rare, aggressive tumors that present unique diagnostic and treatment challenges. In this accredited activity podcast, leading experts Dr. Andrew E. Hendifar and Dr. Danielle Hutchings from Cedars-Sinai Medical Center share practical strategies and emerging evidence on diagnosis, current therapies, and novel treatment targets.Listen now to gain actionable insights and stay current on evolving approaches in EP-NECs!Click the link to claim your CE credit: https://bit.ly/488fPhK
Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD.Building on the foundation of biomarker-driven care, this module focuses on optimizing treatment strategies for patients with esophagogastric cancer. Dr. Janjigian reviews the latest evidence on targeted therapies, immunotherapies, and combination regimens, as well as practical considerations for sequencing and selecting therapies. Gain actionable insights to enhance collaborative care and deliver the most effective, individualized treatment plans for your patients. Listen now!Click here to claim credit for this activity: bit.ly/3HtOziOClick here to listen to Module 1 of this series: bit.ly/45u106o
Esophagogastric Cancer: Enhancing Outcomes Through Biomarkers and Collaborative Care is an accredited, two-part series led by expert Yelena Y. Janjigian, MD.In module 1, Dr. Janjigian provides an in-depth overview of the latest biomarkers—such as HER2, PD-L1, MMR/MSI-H, CLDN18.2, and FGFR2—and their role in guiding treatment decisions for esophagogastric cancer. Learn about current biomarker testing methods, interpretation of results, and how to integrate biomarker data into clinical practice to personalize therapy and improve patient outcomes. Listen now!Click here to claim you CE credit for this activity: bit.ly/45u106oClick here to continue listening to Module 2 of this series: bit.ly/3HtOziO
Genetic testing and counseling are crucial components of precision medicine in cancer care, enabling clinicians to deliver the right care, to the right patient, at the right time. i3 Health’s educational activity, Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, provides a comprehensive foundation for incorporating these tools into practice. In this follow-up interview to the activity, co-chairs Dr. Filipa Lynce, Director of the Inflammatory Breast Cancer at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor at MD Anderson Cancer Center, share advances that have occurred in the field since the activity was recorded, including clinical trial updates and novel insights for clinicians. Click here to complete the free CME/NCPD/CE activity: https://bit.ly/3HqXjpX
i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC).In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity!Click below to complete the claim your CE credit:Module 2: bit.ly/405xEJOClick below to complete the Module 1 from this series, HER2 in NSCLC: Actionable Insights and Testing RecommendationsModule 1: bit.ly/49NCaQu
i3 Health recently launched an exciting new online educational activity, “What’s New with HER2: Charting New Paths in NSCLC Care.” This two-part series dives deep into the evolving role of HER2 in non–small cell lung cancer (NSCLC).In a special interview, Dr. Julia Kathleen Rotow—Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School—shares the latest breakthroughs in treating HER2-mutated NSCLC. She highlights why ongoing medical education is crucial in this fast-changing field and offers her insights on where HER2-targeted therapies are headed next. Stay tuned after the interview to listen to Module 1 of this accredited activity!Click below to complete the claim your CE credit:Module 1: bit.ly/49NCaQuClick below to complete the next Module in this series, Current and Emerging Treatments for HER2-Mutated NSCLCModule 2: bit.ly/405xEJO
For patients with ulcerative colitis, newly developed therapies and tailored treatment strategies have allowed for a more personalized approach to achieving disease control and remission. In this special podcast interview, Dr. Benjamin Cohen, Co-Section Head and Clinical Director of Inflammatory Bowel Diseases at the Cleveland Clinic, offers a behind-the-scenes look at i3 Health’s Virtual Escape Room, which follows Shawn, a 32-year-old man living with ulcerative colitis. Dr. Cohen discusses the greatest challenges in diagnosis and treatment, the importance of staying current with novel therapies and biomarkers, and how this engaging, gamified format not only enhances learning but also translates to improved patient outcomes.Click here to complete the escape room and claim free CME credit!https://i3Health.com/uc-escape
Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Waqas Haque, a Hematology/Oncology Fellow at the University of Chicago, recently shared his perspectives on i3 Health’s CME activity, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With MCED testing moving from research to real-world practice, Dr. Haque discussed the science, challenges, and future of these innovative tests, as well as the importance of staying up to date on emerging advances with continuing education.Click the links below for the full CME activity!Module 1: bit.ly/3X8apxaModule 2 : bit.ly/41rS14IModule 3: bit.ly/4b9JU00And view the slide decks here:Module 1: bit.ly/4l0NTzcModule 2: bit.ly/4fdXwtiModule 3: bit.ly/40AkmoP
As research in dedifferentiated liposarcoma (DDLPS) continues to advance, the importance of multidisciplinary collaboration and access to innovative therapies remains at the forefront of patient care. Recently, Dr. Richard Riedel of Duke Cancer Institute and Dr. Candace Haddox of Dana-Farber Cancer Institute co-chaired i3 Health’s DDLPS Task Force activity, which brought together a panel of experts to address the complexities of this rare and challenging sarcoma subtype. With new clinical trials underway and a growing understanding of the disease’s molecular landscape, Dr. Riedel and Dr. Haddox sat down to highlight promising research directions and insights in honor of Sarcoma Awareness Month in July.After listening to the interview, stay tuned to hear the full accredited podcast with Dr. Riedel and Dr. Haddox, and click the link below to claim free CME/AAPA credit.Click the links below for the Task Force activity! - Accredited CME/AAPA Podcast: https://i3health.com/course-information/podcast-ddlps- Position Statement Published in Cancer Treatment Reviews: https://www.cancertreatmentreviews.com/article/S0305-7372(24)00175-0/fulltext- Live Task Force Recording: https://youtu.be/Otr5_tiFQ68
Join i3 Health for a special live webinar, Increasing Detection and Improving Outcomes in Hereditary Transthyretin Amyloid Cardiomyopathy, being held on Wednesday, July 30 at 5:00 pm ET. In this exclusive event, Dr. Mathew Maurer, the Arnold and Arlene Goldstein Professor of Cardiology at Columbia University Irving Medical Center, will share his expertise and latest insights in the treatment of hereditary ATTR-CM.In this interview, Dr. Maurer shares a preview of the topics he is excited to highlight during the webinar, including signs and symptoms to aid in early diagnosis, advances in genetic testing and new diagnostic modalities, novel therapies that are improving outcomes, and the role of interdisciplinary collaboration.Don’t miss this opportunity to learn from one of the leading voices in hereditary ATTR-CM care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you!Register Here: https://bit.ly/3UgV7nF
Join i3 Health for a special live webinar, Optimizing Neuroendocrine Tumor Outcomes: Closing the Gaps in Diagnosis and Care, being held on Thursday, July 17th at 12:00 pm Eastern and on Tuesday, August 5th at 3:00 pm Eastern. In this exclusive event, Dr. Aman Chauhan, Leader of the Neuroendocrine Tumor Program at the University of Miami, Sylvester Comprehensive Cancer Center, will share his expertise and latest insights in the treatment of NETs.In this interview, Dr. Chauhan shares a preview of the topics he is excited to highlight during the webinar, including the recent advances which are transforming patient care, the emerging field of theranostics, the evolving role of multidisciplinary care, and practical tips for effective team collaboration.Don’t miss this opportunity to learn from one of the leading voices in NETs care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you!Register Here! July 17, 2025 @ 12:00 PM ET: https://us02web.zoom.us/webinar/register/WN_2VJ0PmYISae4gAh2KxNlnQ#/registration August 5, 2025 @ 3:00 PM ET: https://us02web.zoom.us/webinar/register/WN_teUE5QgyQJ6sYaLRrkNp9g#/registration
Biliary tract cancer (BTC) presents a complex puzzle for the interprofessional healthcare team. With its diverse subtypes and unique molecular features, diagnosis and treatment require a personalized approach. Stay ahead of the curve with insights from leading experts, Dr. Anjana Pillai and Dr. Rachna Shroff, as they explore the latest genomic research, targeted therapies, and emerging treatment strategies in this dynamic podcast. Listen now to hear the Multidisciplinary Task Force perspective and strategies to optimize patient care in this rapidly evolving landscape.Click here to claim credit for this podcast:
Join us for a special live webinar, Slowing Disease Progression and Optimizing Quality of Life for Patients With ALS, on Wednesday, June 11th at 1:00 pm Eastern. In this exclusive event, Dr. Richard S. Bedlack will share his expertise and latest insights on ALS care.In this preview interview, Dr. Bedlack discusses his unique approach to supporting patients, including his innovative "Stitching Strength" philosophy, and highlights new research on hope-boosting instruments for people living with ALS. He also offers a glimpse into the key topics and messages he’ll be covering during the webinar, all aimed at helping clinicians and caregivers slow disease progression and enhance quality of life for their patients.Don’t miss this opportunity to learn from one of the leading voices in ALS care. Register at the link below or scan the QR code in the video to secure your spot. We look forward to seeing you on June 11th!Click here to register now: https://bit.ly/3Zjb8wm
In this concluding module, Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, addresses the critical challenges of managing treatment-associated toxicities in the era of advanced melanoma therapies. Discover practical strategies for handling immune-related adverse events, implementing comprehensive supportive care, and optimizing patient education. This podcast is critical for oncology professionals seeking to balance therapeutic efficacy with quality of life for patients receiving cutting-edge immunotherapy and targeted treatments.Click here to go back and listen to module 1 of this podcast series: bit.ly/4iYmYD2Click here to claim your CME/NCPD credit: bit.ly/44yO9RB
Join melanoma authority Michael A. Davies, MD, PhD, University of Texas, MD Anderson Cancer Center, as he navigates the latest breakthroughs in immunotherapy and targeted treatments transforming outcomes for patients with melanoma. Discover how predictive biomarkers, strategic combination therapies, and personalized treatment sequencing are revolutionizing care across neoadjuvant, adjuvant, and metastatic settings. This podcast is essential listening for oncology professionals seeking evidence-based approaches to combat this challenging disease affecting over 100,000 Americans annually.Click here to listen to module 2 of this podcast series: https://bit.ly/44yO9RBClick here to claim your CME/NCPD credit: https://bit.ly/4iYmYD2
Join Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, in Module 1 of this podcast series as she explores the challenges of diagnosing systemic mastocytosis (SM), a rare and often under recognized mast cell disease. In this episode, Dr. Castells discusses the wide range of SM symptoms—including anaphylaxis, cutaneous, gastrointestinal, neuropsychiatric, and musculoskeletal manifestations—and offers essential guidance on recognizing the signs, confirming the diagnosis, and improving patient outcomes through early intervention. Listen now to enhance your clinical knowledge and be sure to claim your credit after the episode!Click on the link to claim your credit now: https://bit.ly/3Y3ivHMClick here to continue listening to Module 2 of this podcast series: https://bit.ly/43VoFNP
Tune in to Module 2 of our podcast series as Dr. Mariana Castells, Director of the Mastocytosis Center at Brigham and Women’s Hospital and Professor of Medicine at Harvard Medical School, explores strategies for developing personalized management plans for patients with systemic mastocytosis (SM). This episode covers the latest advancements in treatment, including tyrosine kinase inhibitors (TKIs), supportive care interventions, and practical approaches to tailoring therapies based on disease subtype and symptom burden. Listen now to stay up to date on best practices for improving patient outcomes and quality of life—and don’t forget to claim your credit after the episode!Click here to claim credit for this activity: https://bit.ly/43VoFNP
The fight against relapsed/refractory multiple myeloma is evolving rapidly, with groundbreaking research and clinical trials paving the way for innovative treatments. But as new therapies emerge, addressing healthcare disparities and improving access to these life-changing advancements has never been more critical.In this episode, Dr. Rahul Banerjee, Assistant Professor of Medicine at Fred Hutchinson Cancer Center and co-chair of i3 Health’s Multiple Myeloma Task Force activity, shares his expert perspective on the latest developments in CAR T-cell therapy and bispecific antibodies. He also highlights ongoing efforts to make these cutting-edge treatments more practical and accessible for patients, ensuring no one is left behind in the fight against this challenging disease.Don’t miss this engaging discussion packed with actionable insights for healthcare professionals. After listening, take the next step by exploring the full Task Force activity and related resources to deepen your understanding and make a difference in your practice.Click below to access these valuable resources:Accredited CME/NCPD Podcast: https://bit.ly/3B4gSB1Position Statement in Blood Cancer Journal: https://www.nature.com/articles/s41408-024-01129-0Live Task Force Recording: https://www.youtube.com/live/TILCPB6w3Ig?si=1Z8m4dA2qwLJd6rN
Schizophrenia is a debilitating mental illness that significantly impacts thought processes, perceptions, emotions, and social interactions. In Module 1 of this podcast, expert Dr. Christoph U. Correll explores the limitations of current dopamine-blocking therapies and discusses ongoing efforts to optimize treatment approaches. Stay informed on the latest advancements in schizophrenia management and enhance your clinical practice.Click here to claim your FREE CME/NCPD/CPE credit:To hear about advances in treatment of schizophrenia with long-acting injectables, continue to Module 2:
Plaque psoriasis is more than just a skin condition—it’s a chronic, immune-mediated disorder that can deeply affect a person’s quality of life. That’s why it’s essential for healthcare professionals to develop effective patient education strategies that address safety concerns, improve communication, and encourage therapy adherence.In this episode, we’re joined by Dr. Steven Feldman, a renowned Professor of Dermatology, Pathology, and Social Sciences & Health Policy at Wake Forest University School of Medicine. Dr. Feldman, who is leading i3 Health’s CME/NCPD/CPE activity Patient Point of View: PDE4 Inhibitors for the Treatment of Adult Plaque Psoriasis, dives into the latest breakthroughs in plaque psoriasis research and shares his expert insights on how these advancements are shaping patient care.Don’t miss this opportunity to expand your knowledge and improve your practice! After listening, be sure to complete the full activity to deepen your understanding and apply what you’ve learned.Click the link below to access the full CME/NCPD/CPE activity! Link to the Activity: https://bit.ly/4hW9ozG
In this episode, Dr. Sabrina Paganoni, Co-Director of the Neurological Clinical Research Institute at Massachusetts General Hospital, discusses the latest advancements in early diagnosis and treatment of amyotrophic lateral sclerosis (ALS), a progressive neurological disorder that leads to motor neuron degeneration and muscle atrophy. Following the interview, listeners can participate in an accredited activity titled Getting Ahead of the ALS Curve Through Early Detection and Intervention: Module 2 – Disease-Modifying Therapies for ALS: Weighing the Options. This activity explores the latest data on FDA-approved and emerging disease-modifying therapies, offering strategies to optimize patient outcomes. Tune in to gain expert insights from Dr. Paganoni and enhance your clinical knowledge while earning continuing education credits.Click here to claim your credit: https://bit.ly/46cNBPO
In this episode, we explore amyotrophic lateral sclerosis (ALS) with Dr. Sabrina Paganoni, Co-Director of the Neurological Clinical Research Institute at Massachusetts General Hospital, who shares insights on early detection and emerging treatments for this progressive neurological disorder. Following the interview, listeners can participate in an accredited activity titled Getting Ahead of the ALS Curve Through Early Detection and Intervention: Module 1 – Enabling Earlier Detection of ALS, which focuses on strategies for enabling earlier ALS detection to improve patient outcomes. Tune in to gain valuable knowledge from Dr. Paganoni and take the next step in advancing your clinical expertise in ALS care while earning continuing education credits.Click here to claim your credit: https://bit.ly/3XwSm4A
March marks Multiple Myeloma Awareness Month, a crucial time to highlight advances in the treatment of this complex blood cancer. Multiple myeloma is the leading indication of autologous hematopoietic stem cell transplantation (ASCT) in hematologic malignancies, with high-dose therapy followed by ASCT representing a potentially curative treatment modality for eligible patients. Dr. Hamza Hashmi, Assistant Attending in the Myeloma & Cell Therapy Service at Memorial Sloan Kettering Cancer Center, is currently serving as chair of i3 Health CME/NCPD activity, Cracking the Code to Successful Stem Cell Mobilization in Multiple Myeloma. In this interview, Dr. Hashmi shares additional insights into the evolving role of transplantation in this disease and the importance of education and advocacy during Multiple Myeloma Awareness Month.Click the link for the full activity! bit.ly/4hyVwLn
As we recognize Kidney Cancer Awareness Month this March, advancements in renal cell carcinoma (RCC) treatment continue to evolve. Recently, Nazy Zomorodian, NP, RNC, MSN, CUNP, CCRC, a Nurse Practitioner and expert in genitourinary oncology, chaired the i3 Health’s NCPD activity titled Toxicity Management and Symptom Control in Advanced RCC: Playbook Update. In this interview, she shares updates in RCC treatment, strategies for toxicity management, and the importance of patient education.Click here for the full NCPD activity! https://i3health.com/course-information/toxicity-management-and-symptom-control-in-advanced-rcc-playbook-update
Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 2 of the activity, including the value of MCED testing for cancer survivors and ongoing trials investigating MCEDs that he’s looking forward to seeing results of in the near future. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit.Click here to claim your CME credit: bit.ly/41rS14I
Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 3 of the activity, including questions he commonly gets from patients about MCED testing and advice for clinicians about employing shared decision making with patients to choose the most appropriate type of cancer screening for them. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit.Click here to claim your CME credit: bit.ly/4b9JU00
Advancements in medical technology are transforming cancer screening, with multicancer early detection (MCED) testing leading the way. Dr. Charles Vega, a Clinical Professor of Family Medicine at the University of California (UC) Irvine, is currently serving as chair of i3 Health’s three-part microlearning series, Optimizing Cancer Screening with MCED Technologies: From Science to Practical Application. With new advances in developing MCED testing and implementing it into practice, Dr. Vega sat down with us again to share additional insights from Module 1 of the activity, including how MCED testing is helping to address the cancer screening gap in the US and the importance of staying up to date on developments in MCED testing. Afterwards, stay tuned to hear the full activity and learn how to claim CME credit.Click here to claim your CME credit: bit.ly/3X8apxa
Cognitive impairment is a core feature of schizophrenia, significantly contributing to functional disability and long-term challenges. Patients often experience poor attention, disorientation, stereotyped thinking, and difficulty with abstract thought, all of which hinder daily functioning and independence.In Module 3 of this podcast, expert Dr. Christoph U. Correll explores current and emerging treatments aimed at improving cognitive function in schizophrenia. Topics include novel pharmacologic strategies, psychosocial interventions, and lifestyle modifications designed to enhance cognitive abilities and overall patient outcomes. Stay informed on the latest research and therapeutic approaches to help optimize care for individuals with schizophrenia.Click here to claim your FREE CME/NCPD/CPE credit:To hear about how to incorporate the latest therapeutic advances for schizophrenia into patient-centered care, continue to Module 4:
Schizophrenia is a highly complex and multifactorial mental illness, with symptoms, presentations, and outcomes varying widely among individuals. Genetic, environmental, and personal factors all play a role in disease progression, making individualized treatment essential for optimal outcomes.In Module 4 of this podcast, expert Dr. Christoph U. Correll discusses how evidence-based strategies, shared decision-making, and holistic recovery approaches can enhance patient care. Learn how to integrate patient experiences, caregiver collaboration, and interdisciplinary teamwork to optimize treatment and improve quality of life for individuals living with schizophrenia.Click here to claim your FREE CME/NCPD/CPE credit:
Schizophrenia affects over 24 million people worldwide, yet treatment adherence remains a significant challenge due to side effects and complex dosing schedules of oral antipsychotics. Long-acting injectables (LAIs) offer a promising alternative, providing less frequent dosing, improved adherence, and more stable blood concentrations, which may lead to better tolerance and reduced toxicity.In Module 2 of this podcast, expert Dr. Christoph U. Correll explores new LAI formulations, extended dosing intervals, and improved initiation strategies to help clinicians optimize treatment adherence and improve patient outcomes. Stay informed on the latest advancements in schizophrenia care.Click here to claim your FREE CME/NCPD/CPE credit:To hear about advances in treatment of cognitive symptoms associated with schizophrenia, continue to Module 3:
Dr. Guy Young, Director of the Hemostasis and Thrombosis Program, Attending Physician in Hematology-Oncology, and Professor of Pediatrics at Keck School of Medicine at the University of Southern California (USC), is currently serving as co-chair of i3 Health’s CME/NCPD activity, Practice-Changing Advances in the Management of Hemophilia. With new developments in the field occurring over recent months, Dr. Young sat down with us to share recent updates in the hemophilia treatment and management. Afterwards, stay tuned to hear the full activity and learn how to claim free CME/NCPD credit.Click the links below for the full activity!Online accredited CME/NCPD activity: https://i3health.com/course-information/practice-changing-advances-in-the-management-of-hemophiliaAccredited CME/NCPD podcast: https://i3health.com/course-information/practice-changing-advances-in-the-management-of-hemophilia-podcast
Implementing AI Into Healthcare Education: The Ethical and Legal Landscape by i3 Health
Tune in to the latest podcast episode, Best Practices and Emerging Evidence in the Treatment of Atopic Dermatitis in Children and Adolescents, where experts Dr. Peter A. Lio and Dr. Linda F. Stein Gold discuss cutting-edge advancements in pediatric AD care. Learn about new therapies, including nonsteroidal topicals, JAK inhibitors, monoclonal antibodies, and emerging treatments targeting the OX40 pathway, along with practical strategies to optimize patient outcomes. This episode is a must-listen for dermatologists, pediatricians, family medicine physicians, nurse practitioners, PAs, nurses, and other healthcare providers looking to stay current on evidence-based care for children and adolescents with AD. Earn CME/NCPD credit while you listen!Click here to claim credit: i3health.com/atopic-dermatitis
Stay ahead in NSCLC management with this accredited podcast! HER2 alterations, including gene mutations and protein overexpression, are key therapeutic targets, but their complexity can challenge treatment decisions.In Module 1 of this podcast, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, provides essential insights and testing recommendations to optimize patient care. Listen now!
Stay ahead in NSCLC management with our accredited podccast! HER2 alterations, including gene amplifications, mutations, and protein overexpression, are critical therapeutic targets, but their heterogeneity can complicate treatment strategies.In Module 2, Dr. Julia Kathleen Rotow, Clinical Director of the Lowe Center for Thoracic Oncology at Dana-Farber Cancer Institute and Assistant Professor of Medicine at Harvard Medical School, explores advanced testing methodologies and strategies to navigate HER2 complexities and optimize patient outcomes. Listen now!
Gain valuable insights into the complexities of diagnosing and managing dedifferentiated liposarcoma (DDLPS) and earn free CME credit with our latest podcast. This episode features expert guidance from Dr. Richard F. Riedel of Duke University and Dr. Candace L. Haddox of Dana-Farber Cancer Institute. Delve into the latest on identifying MDM2 and CDK4 amplification, challenges in diagnosing DDLPS, and updates on emerging therapies like CDK4/6 inhibitors and immunotherapies. Learn how a multidisciplinary approach enhances patient outcomes in this rare and aggressive soft tissue sarcoma. Listen now and advance your expertise!Click here to claim your CME credit: https://i3health.com/course-information/podcast-ddlps
Click the links below for the full activity! Online Accredited CME/NCPD Activity: https://i3health.com/course-information/Alzheimer-disease Live In-Person or Virtual Meeting: https://i3health.com/live/Exploring%20Advances%20in%20the%20Early%20Diagnosis%20and%20Treatment%20of%20Alzheimer%20DiseaseNovember is National Alzheimer Disease Awareness Month, a time to raise awareness of early warning signs, advocate for research, and show support for the more than 6.2 million Americans living with this disease. Dr. Nathaniel Chin, Associate Professor of Medicine in the Division of Geriatrics and Gerontology at the University of Wisconsin-Madison, is currently serving as chair of i3 Health’s accredited CME/NCPD activity, Exploring Advances in the Early Diagnosis and Treatment of Alzheimer Disease. In honor of National Alzheimer Disease Awareness Month, he sat down with us again to share recent advances in diagnosis and treatment, including those which listeners can learn more about in the activity,
i3 Health is pleased to invite you to Pathways to Precision: Integrating Genetic Counseling and Testing Into Cancer Care, a free, live webinar held on November 7 at 10:00 am Eastern and November 19 at 11:30 am Eastern. This interview features an exclusive preview from the two webinar co-chairs, Dr. Filipa Lynce, Director of the Inflammatory Breast Center at Dana-Farber Cancer Center and Assistant Professor of Medicine at Harvard Medical School, and Catherine Skefos, Certified Genetic Counselor in the Clinical Cancer Genetics Program at the University of Texas MD Anderson Cancer Center. Click below to register for this insightful webinar and enhance your understanding of genetic testing and counseling in cancer care!Register for the webinar: https://i3health.com/course-information/pathways-to-precision-integrating-genetic-counseling-and-testing-into-cancer-care
Dr. Deborah Wong, Director of the Medical Oncology Program and Clinical Trials Program for Head and Neck Squamous Cell Cancers (HNSCC) and an Associate Clinical Professor of Medicine at the University of California Los Angeles (UCLA) is currently serving as co-chair of i3 Health’s accredited CME/NCPD activity, Recurrent and Metastatic HNSCC, Harnessing Immunotherapy and Comprehensive Care. With new developments in the field occurring over recent months, Dr. Wong sat down with us again to share new updates in treatment and management of HNSCC.Click here for the full activity! https://i3health.com/course-information/hnscc-harnessing-immunotherapy-in-comprehensive-care
Jeff Sperry, PharmD, BCPS, a Clinical Pharmacist at UCHealth Memorial Hospital, sat down with the Pharmacy Podcast Network to discuss additional advances in chronic kidney disease since recording the i3Health CPE-accredited activity, Slowing Progression of Chronic Kidney Disease Through Value-Based Care. Following the interview, continue listening for the complete CPE-accredited podcast.Click this link to claim your free CPE certificate: i3health.com/course-information…nic-kidney-disease
Dr. Nathaniel Chin, Associate Professor of Medicine in the Division of Geriatrics and Gerontology at the University of Wisconsin-Madison, is currently serving as chair of i3 Health’s accredited CME/NCPD activity, Exploring Advances in the Early Diagnosis and Treatment of Alzheimer Disease. With new developments in the field occurring over recent months, Dr. Chin sat down with us again to share new updates in treatment and management of Alzheimer disease and what clinicians can look forward to learning more about in the online activity and webinars. Click the links below for the full activity! Online Accredited CME/NCPD Activity: https://i3health.com/course-information/Alzheimer-diseaseLive Webinar: https://i3health.com/course-information/exploring-advances-in-the-early-diagnosis-and-treatment-of-alzheimer-disease-webinarIn-Person or Virtual Meeting: https://i3health.com/live/Exploring%20Advances%20in%20the%20Early%20Diagnosis%20and%20Treatment%20of%20Alzheimer%20Disease
Listen now to this CME-accredited podcast, part of the Multiple Myeloma Task Force series, where we will explore strategies for mitigating disease burden and addressing health care disparities in patients with relapsed/refractory multiple myeloma. This session brings together expert insights from Task Force Co-Chairs, Dr. Sikander Ailawadhi, Professor of Medicine at Mayo Clinic, and Dr. Rahul Banerjee, Assistant Professor of Medical Oncology at Fred Hutchinson Cancer Center and the University of Washington. Their consensus-driven perspectives will provide valuable guidance on improving patient outcomes and equity in care for multiple myeloma.To learn more about the task force, read the position statement or revisit the youtube live please visit: https://i3health.com/course-information/podcast-rrmm
Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application.In Module 3 of our CME podcast, Dr. Charles Vega, Clinical Professor at the University of California, Irvine, will review the latest clinical trial data on MCED tests for gynecologic, gastrointestinal, and hematologic cancers, offering valuable insights into how these innovations could transform cancer screening and improve patient outcomes.Claim your free CME credit here:
Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application. Listen now to Module 1 and join Dr. Charles Vega, a distinguished Clinical Professor from UC Irvine, as he explores the cutting-edge realm of multicancer early detection (MCED). Dr. Vega will delve into the scientific foundations of blood-based cancer screening, highlighting both current limitations and the promising potential of MCED technologies. Learn how these revolutionary tests harness biomarkers to detect multiple cancers in a single, convenient screening—a game-changer in overcoming barriers like low awareness and limited access to screening facilities.Claim your free CME credit for this activity podcast here:
Discover the future of cancer screening with our exclusive CME podcast series, Optimizing Cancer Screening With MCED Technologies: From Science to Practical Application.Join Dr. Charles Vega in Module 2 of our CME podcast as he delves into the cutting-edge world of multicancer early detection (MCED) tests. With nearly 2 million new cancer cases expected in 2024, the role of early detection has never been more critical. Dr. Vega will unpack the latest clinical trial data on MCED tests for gynecologic, gastrointestinal, and hematologic cancers, exploring their potential to revolutionize cancer screening and improve patient outcomes.Listen now and claim your free CME credit here:
Dr. Timothy John Feyma, Pediatric Neurologist at Gillette Children’s Hospital, is currently serving as chair of i3 Health’s CME/NCPD activity, Exploring Novel Treatments for Rett Syndrome. With new developments in the field occurring over recent months, Dr. Feyma sat down with us again to share new updates in treatment and management of Rett syndrome, words of advice for how clinicians can best care for their patients, and what he is most looking forward to seeing in Rett syndrome research in the coming years. Click here to view Dr. Feyma’s full CME/NCPD activity and claim credit: https://i3health.com/course-information/rett-syndromeClick here to register for a live webinar presented by Dr. Feyma: https://i3health.com/course-information/rett-syndrome-webinarClick here to bring an in-person or virtual meeting to your own institution: https://i3health.com/live/exploring-novel-treatments-for-rett-syndrome-2
In this podcast, hear expert perspectives on practice-changing advances in the treatment and personalized management of patients with hemophilia from Dr. Guy Young, Director of the Hemostasis and Thrombosis Program, Attending Physician in Hematology/Oncology, and Professor of Pediatrics at Keck School of Medicine of USC; and Dr. Jennifer Davila, Co-Director of the Hemophilia Treatment Center at Montefiore and Associate Professor of Pediatrics at The Children's Hospital at Montefiore. Listen to the episode now!
In this video, Dr. Jamie E. Chaft, Associate Attending Physician at Memorial Sloan Kettering Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Leveraging the Growing Arsenal of Therapies for Early-Stage Non–Small Cell Lung Cancer (NSCLC), chaired by Dr. Helena Yu. Dr. Chaft shares insights into emerging roles of measurable residual disease (MRD) in lung cancer, the significance of the recent approval of alectinib for ALK-positive disease, treatment considerations for older versus younger patients, important research updates at the American Society of Clinical Oncology (ASCO) Annual Meeting, and more!Interested in completing this activity and earning FREE CME/NCPD credit? Click here: https://bit.ly/4b3QDXJ
In this video, Dr. Catherine M. Broome, Professor of Medicine at Georgetown University Medical Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Putting the Freeze on Cold Agglutinin Disease (CAD). Dr. Broome shares insights into resources she recommends for patients with CAD, the role of thromboprophylaxis, treatment advances to expect within the next year, the most important things for primary care providers and non-hematologists to know about CAD, and more!Interested in completing this activity and earning FREE CME/NCPD credit? Click here: https://bit.ly/45s11qT
In Module 2 of this microlearning series and podcast, Dr. Sabrina Paganoni, Co-Director of the Neurological Clinical Research Institute at Massachusetts Hospital and Healey & AMG Center for ALS, and Associate Professor of Physical Medicine and Rehabilitation (PM&R) at Spaulding Rehabilitation Hospital of Harvard Medical School, will share strategies for weighing the options of disease-modifying therapies for ALS.
In Module 1 of this microlearning series and podcast, Dr. Sabrina Paganoni, Co-Director of the Neurological Clinical Research Institute at Massachusetts Hospital and Healey & AMG Center for ALS, and Associate Professor of Physical Medicine and Rehabilitation (PM&R) at Spaulding Rehabilitation Hospital of Harvard Medical School, will share strategies for getting ahead of the ALS curve by enabling earlier detection.
Last year, Dr. Sara Tolaney, Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute, served as co-chair of i3 Health’s webinar and online activity, Pathology and Oncology Expert Perspectives in the Management of Triple-Negative Breast Cancer (TNBC). With numerous advances in TNBC research occurring since then, Dr. Tolaney sat down with Oncology Data Advisor to share additional updates from clinical trials and a preview into the future of treatment with emerging therapies for TNBC.To complete the CME/NCPD activity, follow this link: https://bit.ly/3KhoDVG
Dr. Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, Fred Hutchinson Cancer Center, is currently serving as chair of i3 Health’s online activity and fellows meeting series, Leveraging BCMA-Directed Therapies for Improved Patient Outcomes in Relapsed/Refractory Multiple Myeloma. Since recording the activity, numerous updates have occurred in research for this field, with the most notable being the recent expanded approvals of idecabtagene vicleucel and ciltacabtagene autoleucel for earlier lines of therapy. In this interview, Dr. Banerjee shares additional insight into these expanded approvals and how they affect the treatment landscape for patients with multiple myeloma.Click the links below for the full activity!Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myelomaLive or Virtual Meeting Series: https://www.i3health.com/live/leveraging-bcma-directed-therapies-for-improved-patient-outcomes-in-relapsedrefractory-multiple-myeloma%20-%20live%20-%20webinar
In this video, Dr. Neal Weinreb, Voluntary Associate Professor for Human Genetics at the University of Miami Miller School of Medicine, answers questions asked by the audience during his CME/NCPD–approved activity with i3 Health, Exploring Treatment Advances for Acid Sphingomyelinase Deficiency (ASMD) in Adults. Dr. Weinreb shares insights into screening for lysosomal storage disorders, genetic carrier testing, resources for family and caregivers, the future of treatment with olipudase alfa, and more.Click the links below for the full activity!Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/exploring-new-treatment-advances-for-acid-sphingomyelinase-deficiency-in-adultsLive or Virtual Meeting Series: https://www.i3health.com/live/exploring-new-treatment-advances-for-acid-sphingomyelinase-deficiency-in-adults-1
In this video, Dr. Assuntina G. Sacco, Associate Professor of Internal Medicine, Co-Director of the Hanna and Mark Gleiberman Head and Neck Cancer Center, and Disease Team Leader–Head and Neck at UC San Diego Moores Cancer Center, answers questions asked by the audience during her CME/NCPD–approved activity with i3 Health, Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: New Insights and Real-World Evidence for Improved Patient Outcomes. Dr. Sacco shares insights into targeted mutations to test for, recommendations for patient education, the future of HPV therapeutic vaccines, monitoring for immune-related adverse events, and more!Claim free CME/NCPD credit for Dr. Sacco's activity here: https://www.i3health.com/course-information/recurrent-and-metastatic-hnscc-new-insights-and-real-world-evidence-for-improved-patient-outcomes
Last year, Brian Rubin, MD, PhD, Chair of Pathology and Laboratory Medicine and the Chief of Diagnostics at the Cleveland Clinic, served as co-chair for i3 Health's continuing medical education CME NCPD #virtualtumorboard: Multidisciplinary Management of Advanced Soft Tissue Sarcoma. In this interview, Dr. Rubin sat down with Oncology Data Advisor to discuss updates in the treatment and management of soft tissue sarcoma, what to look forward for the future of treating sarcomas, and his passion for this field. Watch the interview now and complete the activity here: https://bit.ly/3tHGzni
Dr. Christopher Lieu, Associate Director of Clinical Research at the University of Colorado Cancer Center and Vice Chair of the National Comprehensive Cancer Network (NCCN), is currently serving as chair of i3 Health's online activity, live webinar, and meeting series, Hitting the Target in HER2-Positive Metastatic Colorectal Cancer. With numerous research advances occurring in this field during the past year, Dr. Lieu sat down with us again to share updates in targeted therapies for HER2-positive metastatic colorectal cancer and the evolving landscape of biomarkers under investigation for this disease.Click the links below for Hitting the Target in HER2-Positive Metastatic Colorectal Cancer, an accredited CME/NCPD activity provided by i3 Health!Online Accredited CME/NCPD Activity: https://www.i3health.com/course-information/hitting-the-target-in-her2-positive-metastatic-colorectal-cancerLive Webinar Registration: https://www.i3health.com/course-information/Colorectal-Cancer-WebinarLive or Virtual Meeting Series: https://www.i3health.com/live/hitting-the-target-in-her2-positive-metastatic-colorectal-cancer-1
Dr. Spero Cataland, Professor of Internal Medicine and the Benign Hematology Section Head at The Ohio State University, Wexner Medical Center, is currently serving as chair of i3 Health's free CME/NCPD activity and Hematology Fellows Lecture Series, Current Standards and New Directions in Treatment of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). In this interview, Dr. Cataland provides an update on new research that has occurred in the field during the past year and shares a preview of what learners can look forward to when attending his presentation at their own institution.Use this link to complete the CME/NCPD activity and claim credit: https://bit.ly/3xxJFvW
Last year, Jaffer Ajani, MD, Professor in the Department of Gastrointestinal (GI) Medical Oncology at MD Anderson Cancer Center, served as co-chair of i3 Health's Virtual Tumor Board, Building Comprehensive Care Plans in Esophagogastric Cancers, along with Lei Zhao, MD, PhD, Assistant Professor of Pathology at Brigham and Women's Hospital, and Kelly Rone, DNP, RN, AGNP-c, Advanced Practice Nurse at the Mayo Clinic. With numerous developments in the field occurring since recording the activity, Dr. Ajani sat down with Oncology Data Advisor to provide an update on the evolving field of esophagogastric cancer research and advances to look forward to in the coming years.Click here to view and claim credit for Building Comprehensive Care Plans in Esophagogastric Cancer, an accredited CME/NCPD activity provided by i3 Health: https://www.i3health.com/course-information/virtual-tumor-board-building-comprehensive-care-plans-in-esophagogastric-cancers
At the recent American Society of Hematology (ASH) Annual Meeting, numerous updates were presented with the potential to impact practice in relapsed/refractory multiple myeloma. While at the meeting, Urvi Shah, MD, Assistant Attending in the Myeloma Service at Memorial Sloan Kettering Cancer Center, shares some of most significant highlights of the clinical trials and therapeutic agents being presented. After listening to the podcast, be sure to watch Dr. Shah's free CME activity or book a live meeting for your institution to hear more expert perspectives on new directions in multiple myeloma treatment! Free CME activity: https://www.i3health.com/course-information/expert-guidance-on-current-standards-and-new-directions-in-newly-diagnosed-multiple-myelomaBook a meeting for your institution: https://www.i3health.com/live/expert-guidance-on-current-standards-and-new-directions-in-newly-diagnosed-multiple-myeloma-1
Recently, Tanya Dorff, MD, Division Chief of the Genitourinary Disease Program at City of Hope, served as faculty for i3 Health's CME/NCPD-approved activity, Evolving Treatment Concepts and New Data in Advanced Prostate Cancer. Since recording, a plethora of new data and treatment options have been made available for prostate cancer, as well as additional ongoing and future clinical trials to look forward to. In this interview, Dr. Dorff catches us up to speed on these new advancements and shares resources and advice for clinicians working in the field of prostate cancer.To view or complete the CME activity, click here: https://bit.ly/3uLwVRb
Recently, Dr. Henry Park, Chief of Thoracic Radiotherapy at Smilow Cancer Network of Yale School of Medicine, served as faculty for i3 Health’s CME/NCPD/CPE–approved activity, Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer (SCLC). This month, numerous updates in the use of radiotherapy for SCLC were presented at the American Society for Therapeutic Radiology and Oncology (ASTRO) Annual Meeting. In this interview, Dr. Park outlines the most significant updates presented at ASTRO and how he plans to incorporate them into the treatment of patients with SCLC. At the end of the interview, stay tuned to hear Dr. Park's full presentation and claim credit at https://gate.sc/?url=https%3A%2F%2Fwww.i3health.com%2Fcourse-information%2Fvideo-viewpoint-strategy-session-optimizing-treatment-selection-sequencing-and-tolerability-in-small-cell-lung-cancer&token=7e964b-1-1698857353561
EXPIRING ON MONDAY, AUGUST 21!
In this podcast from i3 Health gain expert insight and enhance your clinical knowledge with this case-based activity focusing on new and groundbreaking biomarkers used for diagnosis of graft-versus-host disease, factors for therapy selection, and clinical trial findings used to individualized treatment for patents, presented by leading faculty Shernan Holtan, MD, Associate Professor of Medicine, University of Minnesota, and Carrie Kitko, MD, Associate Professor of Pediatrics, Vanderbilt University Medical Center. Start the activity now!
Click here to claim CME/NCPD/CPE credit: i3health.com/oda-gvhd
Hurry! This activity expires on Tuesday, August 15!
This podcast episode from i3 Health is presented by Ariela Noy, MD, and Matthew Matasar, MD, of Memorial Sloan Kettering Cancer Center will explore how to determine when marginal zone lymphoma (MZL) treatment should be initiated and will discuss the latest research on therapeutic strategies and their application in the clinic. Listen now!
Click here to claim you free CME/NCPD credit: bit.ly/3OFBxiX
Presented by Dr. Shawn Kwatra, Director, Johns Hopkins Itch Center, Associate Professor of Dermatology, Johns Hopkins University School of Medicine and Dr. Linda Stein Gold, Director of Dermatology Clinical Research, Division Head of Dermatology, Henry Ford Health System, this expert led discussion will direct thoughtful consideration of the health care disparities faced by Black patients with AD, best practices in diagnosis and assessment, and the applicability of novel therapeutic approaches for moderate-to-severe disease.
Click here to claim credit: i3health.com/atopic-dermatitis
In recent years, numerous developments have occurred in metastatic castration-resistant prostate cancer (CRPC) treatment and management. Last year, Kathleen Burns, MSN, NP, Nurse Practitioner in the Division of Genitourinary Medical Oncology at City of Hope Comprehensive Cancer Center, recorded an activity with i3 Health titled Overcoming Nursing Management Challenges in Metastatic Castration-Resistant Prostate Cancer. At the 48th Annual Oncology Nursing Society Congress this April, she sat down with Oncology Data Advisor to share the updates in nursing management strategies for CRPC that have occurred in this field since recording.
Click here to view and claim credit for Overcoming Nursing Management Challenges in Metastatic Castration-Resistant Prostate Cancer, an accredited NCPD activity provided by i3 Health: https://i3health.com/mcrpc
Click here to view and claim credit for Managing Toxicities of Novel Breast Cancer Therapies: PI3K Inhibitors, an accredited CME/NCPD/CPE activity by i3 Health: https://i3health.com/odabc-pi3k.Phosphatidylinositol-3-kinase (PI3K) inhibitors are effective treatment for patients with breast cancer but can be associated with significant hyperglycemia and rash. In this interview from the 48th Annual Oncology Nursing Society (ONS) Congress, Janie Metsker, RN, BSN, CN-BN, Clinical Coordinator at St. Luke’s Koontz Center for Advanced Breast Cancer, shares updated strategies for managing these toxicities in order to provide the best outcomes for patients with breast cancer receiving PI3K inhibitors.
Click here to claim CME/NCPD credit for this activity: i3health.com/oda-gvhdThis audio includes both the additional updates interview and complete podcast from i3 Health’s CME/NCPD activity New Opportunities for Improved Patient Outcomes in Graft-Versus-Host Disease.First, listen along as Dr. Shernan Holtan shares the latest data from the BTM CTN 1703 trial of posttransplant cyclophosphamide, tacrolimus, and mycophenolate mofetil as GVHD prophylaxis after allogeneic hematopoietic cell transplantation, then stay tuned after the interview to listen along to the full activity.
This expert-led episode of Oncology Data Advisor TM, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine.ain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, Start the activity now!Click the link to claim your free CME/NCPD credit: https://i3health.com/oda-ec
In 2022, Dr. Maura Abbott, Associate Professor of Nursing at the Columbia University School of Nursing, served as faculty for i3 Health’s CME/NCPD approved activity, New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia. Now, in this follow-up interview with Oncology Data Advisor, Dr. Abbott reinforces the importance of educating patients who are at risk for chemotherapy-induced neutropenia and shares some of the therapeutic developments in both prevention and management that are coming down the pipeline in the near future. Listen to the free CME/NCPD activity, New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia, after the interview and click here to claim credit: https://i3health.com/44-policies/503-i3health-com-cin
In this expert-led episode of Oncology Data AdvisorTM, presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing,will explore recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. Listen now to earn free CME|NCPDClick here to claim credit: i3health.com/oda-cin
Last year, Dr. Ticiana Leal, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, recorded a continuing medical education (CME)/nursing continuing professional development (NCPD)–accredited activity titled Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer (NSCLC). With numerous developments in the field occurring since recording the activity, including new FDA approvals and clinical trial results, Dr. Leal sat down with Oncology Data Advisor to provide an update on the rapidly evolving field of NSCLC immunotherapy. Click here to view and claim credit for Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/nsclc-immunotherapy
This expert-led episode of Oncology Data Advisor™, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non–small cell lung cancer. Listen now to earn free CME/NCPD!Click here to claim credit: i3health.com/oda-nsclc-immunotherapy
In 2022, Dr. Shernan Holtan, Associate Professor at the University of Minnesota Medical School, recorded a CME/NCPD activity centered on new therapeutic avenues for improved patient outcomes in graft-versus-host-disease (GVHD). Recently, at the American Society of Hematology (ASH) Annual Meeting, she presented results of the BMT CTN 1703 trial, which investigated the efficacy of a GVHD prophylaxis regimen. While there, Dr. Holtan sat down with Oncology Data Advisor to discuss the potential of these results to change GVHD prophylaxis, as well as the other significant GVHD research presented at the meeting. Click here to view and claim credit for New Opportunities for Improved Patient Outcomes in Graft-Versus-Host Disease, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/gvhd
Click here to view and claim credit for Harnessing Immunotherapy-Based Strategies for Advanced Non–Small Cell Lung Cancer, an accredited CME/NCPD activity provided by i3 Health: i3health.com/nsclc-immunotherapyJust under a year ago, Beth Sandy, MSN, CRNP, a Thoracic Oncology Nurse Practitioner at the University of Pennsylvania Abramson Cancer Center, co-led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity, Harnessing Immunotherapy-Based Strategies For Advanced Non–Small Cell Lung Cancer (NSCLC). In this interview, she provides an update on advancements made in treatment and supportive care strategies since recording.
This 2-module continuing pharmacy education—(CPE) Strategy Session brings together 2 expert pharmacists to discuss treatment goals and value-based care for patients with newly diagnosed multiple myeloma. Learners must complete both modules to receive credit.In Module 1 of this CPE-approved activity, Joseph A. Kalis, PharmD, BCOP, Ambulatory Oncology Clinical Pharmacy Specialist at the University of Colorado Health, will explore evolving treatment paradigms in newly diagnosed multiple myeloma, including the efficacy and safety of anti-CD38 monoclonal antibodies and supportive care considerations for their use.In Module 2 of this CPE-approved activity, Eric Cannon, PharmD, FAMCP, Chief Pharmacy Benefits Officer at SelectHealth, will explore strategies for aligning treatment goals and value-based care for patients with newly diagnosed multiple myeloma.Listen now and click here to claim credit: https://i3health.com/oda-mm-treatment
In 2022, Allison Imahiyerobo, an Advanced Practice Nurse at the Englewood Health Physician Network in New Jersey, led a continuing medical education (CME)/nursing continuing professional development (NCPD)–approved activity with i3 Health, New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia. A year later, Ms. Imahiyerobo sat down with Oncology Data Advisor to discuss additional advancements and updates in ITP management and patient care since recording.Click here to view and claim credit for New Insights and Avenues for Improved Patient Outcomes in Immune Thrombocytopenia, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/patient-outcomes-itp
In 2022, Dr. Maura Abbott, Associate Professor of Nursing at the Columbia University School of Nursing, served as faculty for i3 Health’s CME/NCPD approved activity, New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia. Now, in this follow-up interview with Oncology Data Advisor, Dr. Abbott reinforces the importance of educating patients who are at risk for chemotherapy-induced neutropenia and shares some of the therapeutic developments in both prevention and management that are coming down the pipeline in the near future.Click here to view and claim credit for New Insights Into Preventing and Managing Chemotherapy-Induced Neutropenia, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/new-cme/44-policies/503-i3health-com-cin
Myelofibrosis is a rare myeloproliferative neoplasm characterized by the buildup of scar tissue in the bone marrow, leading to decreased erythropoiesis, progressive bone marrow failure, and anemia. Currently, the discovery of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway's role in the pathogenesis of myelofibrosis is transforming the landscape with novel agents that improve patients' outcomes. However, correctly diagnosing and managing this disease using novel therapies and strategies remains challenging for clinicians.To complete the activity and claim free CME/NCPD, visit: https://i3health.com/mf
In January 2022, Dr. Amir Fathi, Associate Professor of Medicine at Harvard Medical School, served as faculty for Therapy of B-Cell Acute Lymphoblastic Leukemia (ALL): an Evolving Landscape, presented during the ODACon Rare Hematologic Malignancies Symposium. Recently, numerous significant updates in both ALL and acute myeloid leukemia (AML) were presented at the 2022 American Society of Hematology (ASH) Annual Meeting in New Orleans. In this interview, Dr. Fathi elaborates on these exciting developments in the ever-changing treatment landscape for acute leukemia. Click here to view and claim credit for Therapy of B-Cell Acute Lymphoblastic Leukemia: an Evolving Landscape, an accredited CME/NCPD/CPE activity provided by i3 Health: https://i3health.com/odacon-all
Visit i3health.com/relapsed-refractory-multiple-myeloma to book a live or virtual meeting at your own institution and hear more expert perspectives from Dr. Kumar or other esteemed multiple myeloma faculty!Currently, Dr. Shaji Kumar, Professor of Hematological Malignancies at the Mayo Clinic Cancer Center, is the chair of Optimizing Treatment Sequencing for Patients With Relapsed/Refractory Multiple Myeloma, a continuing medical education/nursing continuing professional development (CME/NCPD)–accredited live or virtual meeting series provided by i3 Health. In this interview, Dr. Kumar provides a glimpse into the exciting developments in multiple myeloma research that are covered in the program, including breaking updates from the 2022 American Society of Hematology (ASH) Annual Meeting.
In 2022, Dr. Mark Kris, the William and Joy Ruane Chair in Thoracic Oncology at Memorial Sloan Kettering Cancer Center, served as chair of Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer (NSCLC), a continuing medical education (CME)/nursing continuing professional development (NCPD) activity. A year later, Dr. Kris sat down again with Oncology Data Advisor to share the progress that has occurred in this field and the important considerations to keep in mind when treating patients with squamous NSCLC in 2023.Click here to view and claim credit for Optimizing Management of Metastatic Squamous Non–Small Cell Lung Cancer, an accredited CME/NCPD activity provided by i3 Health: https://i3health.com/squamous-nsclc
Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This podcast is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Listen now to earn free CME/NCPD!To claim credit, click here: https://i3health.com/oda-squamous-nsclc
Since the original activity, Treatment Advances in Waldenstrom Macroglobulinemia, was originally presented and recorded, there have been several significant updates in the treatment and management of WM.Dr. Gertz recently sat down with Oncology Data Advisor again to discuss these updates and share all that has occurred in this evolving field. Don't miss out on these updates and listen to the interview after you've completed the activity!If you haven't already listened to the activity, click here: https://on.soundcloud.com/f6san
In this case-based discussion, Morie Gertz, MD, Chair of General Internal Medicine at the Mayo Clinic in Minnesota, will discuss how to use predictive and prognostic markers to select treatment for patients with Waldenstrom macroglobulinemia (WM) and how to appraise emerging clinical trial data and adverse event management strategies for novel treatments. Listen now to earn free CME/NCPD/CPE!Click here to claim credit: bit.ly/3PGfd6Z
This podcast, presented by Mikkael Sekeres, MD, Chief of the Division of Hematology at the University of Miami Health System, will focus on predictive and prognostic markers for myelodysplastic syndromes (MDS), emerging data on novel therapies, and strategies to optimize safety and tolerability for patients with this disease. Listen now to earn free CME/NCPD/CPE!Claim credit here: bit.ly/3yI6GJo
This in-depth discussion, presented by Louis Diehl, MD, Professor of Medicine at Duke University Medical School, will feature strategies for incorporating predictive and prognostic markers, recent efficacy and safety data, and adverse event management strategies into treatment selection for patients with Hodgkin lymphoma (HL). Listen now to earn free CME/NPCD/CPE!Click here to claim credit: bit.ly/3PdghPj
Discover insights on predictive and prognostic markers, emerging efficacy and safety data, strategies to optimize tolerability for patients receiving novel therapies for mantle cell lymphoma (MCL), and more in this case-based activity presented by John Leonard, MD, the Richard T. Silver Distinguished Professor of Hematology and Medical Oncology at Weill Cornell Medicine. Listen now!Click here to claim CME/NCPD/CPE credit: bit.ly/3cy6PrK
Presented by Amir Fathi, MD, Associate Professor of Medicine at Harvard Medical School, this activity will highlight individualized treatment selection for patients with acute lymphoblastic leukemia (ALL), as well as recent efficacy and safety data for novel therapeutic strategies. Listen now to earn free CME | NCPD | CPE!Click here to claim credit: https://bit.ly/3FUDtji
This activity expires on MONDAY, DECEMBER 5!
In this podcast episode from i3 Health, expert faculty provide insight on new data and emerging strategies for patients with migraine headaches including prevention, treatment, and strategies for management related to adverse events and supportive care. Presented by Jessica Ailani, MD, Director, MedStar Georgetown Headache Center, MedStar Georgetown University Hospital, and Calli Cook, DNP, APRN, FNP-C, FAANP, Clinical Assistant Professor, Nell Hodgson Woodruff School of Nursing, Emory University. Listen now!
Click here to claim CME/NCPD/CPE credit: i3health.com/podcast-migraine
This case-based podcast presented by i3 Health brings together two leading experts, Anne Chiang, MD, PhD, Associate Professor of Medicine, and Henry Park, MD, MPH, Chief of the Thoracic Radiotherapy Program, both at Yale School of Medicine, who will examine recent clinical advances and new opportunities in the management of SCLC and discuss key clinical questions engendered by recent advances in treatment and the need for individualized care. Listen now!
Click here to claim CME/NCPD/CPE credit: https://i3health.com/sclc-treatment
In this podcast from i3 Health gain expert insight and enhance your clinical knowledge with this case-based activity focusing on new and groundbreaking biomarkers used for diagnosis of graft-versus-host disease, factors for therapy selection, and clinical trial findings used to individualized treatment for patents, presented by leading faculty Shernan Holtan, MD, Associate Professor of Medicine, University of Minnesota, and Carrie Kitko, MD, Associate Professor of Pediatrics, Vanderbilt University Medical Center. Start the activity now!
Click here to claim CME/NCPD credit: https://i3health.com/oda-gvhd
This expert-led discussion presented by Aaron Goodman, MD, Hematologist/Oncologist and Associate Professor of Medicine at UC San Diego Health provides the latest insights on diagnosing T-cell lymphoma, including subtypes; efficacy and safety data for novel agents; tailoring treatment plans to individual patients; applying strategies to manage symptoms and optimize a patient’s quality of life; and much more!
Click here to claim CME or NCPD credit for this podcast: https://i3health.com/t-cell-lymphoma
This podcast episode from i3 Health is presented by Ariela Noy, MD, and Matthew Matasar, MD, of Memorial Sloan Kettering Cancer Center will explore how to determine when marginal zone lymphoma (MZL) treatment should be initiated and will discuss the latest research on therapeutic strategies and their application in the clinic. Listen now!
Presented by Dr. Shawn Kwatra, Director, Johns Hopkins Itch Center, Associate Professor of Dermatology, Johns Hopkins University School of Medicine and Dr. Linda Stein Gold, Director of Dermatology Clinical Research, Division Head of Dermatology, Henry Ford Health System, this expert led discussion will direct thoughtful consideration of the health care disparities faced by Black patients with AD, best practices in diagnosis and assessment, and the applicability of novel therapeutic approaches for moderate-to-severe disease.
Click here to claim credit: https://i3health.com/podcast-atopic-dermatitis
This expert-led episode of Oncology Data Advisor TM, presented by leading experts Ritu Salani, MD, Director of the Division of Gynecologic Oncology and Professor of Obstetrics and Gynecology at the University of California, Los Angeles (UCLA), and Floor Backes, MD, Professor of Obstetrics and Gynecology at The Ohio State University College of Medicine.ain expert insight and enhance your clinical knowledge with this case-based activity focusing on the pathology, treatment, and management of advanced endometrial cancer, Start the activity now!
Click here to claim credit: https://i3health.com/oda-ec
In this expert-led episode of Oncology Data AdvisorTM, presented by Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP, Professor, University of Washington, and Maura Abbott, PhD, AOCNP®, CPNP, Columbia University School of Nursing,will explore recent developments in the prevention, treatment, and management of chemotherapy-induced neutropenia, including a comprehensive understanding of the risk factors and current clinical practice guidelines. Listen now to earn free CME|NCPD
Click here to claim credit: https://i3health.com/oda-cin
This expert-led episode of Oncology Data Advisor™, presented by Ticiana Leal, MD, Director of the Thoracic Medical Oncology Program at Winship Cancer Institute of Emory University, and Beth Sandy, MSN, CRNP, Thoracic Oncology Nurse Practitioner at Abramson Cancer Center of University of Pennsylvania, will focus on emerging efficacy and safety data on immunotherapy-based strategies, supportive care plans for adverse events, and optimizing care plans for the survivorship of patients with non–small cell lung cancer. Listen now to earn free CME/NCPD!
Click here to claim credit: https://i3health.com/oda-nsclc-immunotherapy
Discover new developments in the management of metastatic squamous non–small cell lung cancer (NSCLC), including individualized care plans, efficacy and safety of novel therapies, and strategies to optimize survivorship for patients with NSCLC. This podcast is presented by expert faculty, Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, and Victoria Sherry, DNP, CRNP, AOCNP®, Nurse Practitioner, Abramson Cancer Center. Listen now to earn free CME/NCPD!
Click here to claim credit: https://i3health.com/oda-squamous-nsclc
In this podcast episode from i3 Health, expert faculty provide insight on new data and emerging strategies for patients with migraine headaches including prevention, treatment, and strategies for management related to adverse events and supportive care. Presented by Jessica Ailani, MD, Director, MedStar Georgetown Headache Center, MedStar Georgetown University Hospital, and Calli Cook, DNP, APRN, FNP-C, FAANP, Clinical Assistant Professor, Nell Hodgson Woodruff School of Nursing, Emory University. Listen now!
Click here to claim credit: https://i3health.com/podcast-migraine
This comprehensive activity podcast episode; presented by faculty experts Aparna Parikh, MD, MS, Harvard Medical School, and Theresa Gillespie, PhD MA, RN, FAAN, Emory University School of Medicine, will focus on practice guidelines, emerging data on treatment combinations, and assessing strategies on improving the quality of patients life with BRAF V600–mutant metastatic CRC.
Click here to claim credit: https://i3health.com/colorectal
Gain expert insight on emerging treatment approaches for patients with head and neck squamous cell carcinoma, incuding the safety and tolerabilty of emerging treatments, survivorship care, and much more. This activity podcast episode is presented by leading experts, Barbara Burtness, MD, Professor of Medicine at Yale School of Medicine and Smilow Cancer Hospital, and Lynsey Teulings, NP, Nurse Practitioner at Yale School of Medicine and Smilow Cancer Hospital. Listen now!
Click here to claim credit: https://i3health.com/oda-hnscc